Key facts
- It has raised $3.8M; the latest was Seed Round ($3.8M) in Jul 2025.
- Notable investors include NRW BANK, Aquarius Invest, Campus Capital, DIGITALHUB.DE, Gateway Accelerator — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Detechgene
- ·The full record, as it builds
Funding rounds
No funding rounds for Detechgene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Detechgene
Developer of a rapid test system of pathogens intended to offer a cartridge system that meets all medical requirements. The company offers a pocket-sized cartridge system with isothermal nucleic acid amplification and visual result read-out for complex equipment, cost-intensive procedures, and technology for the detection of pathogens, enabling clinics, researchers, and individuals to perform accurate and user-friendly infectious disease testing and doctors to diagnose their patients' illnesses on-site.
- Sector
- Healthcare
- HQ
- Cologne, Germany
- Founded
- 2022
- Employees
- 9
- Website
- detechgene.de/
- Ownership
- Privately Held (backing)
Detechgene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Detechgene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Detechgene in its N-PORT filings yet. We sweep new filings monthly.